Enteric capsule containing corynebacterium fenfen
By developing enteric-coated capsules of Fenix-type Bacillus, the demand for special drugs for patients with chemotherapy-related diarrhea is solved. The optimized formula of bacterial powder and water absorbents has improved the acid resistance and stress resistance of probiotics, and significantly improved the symptoms of diarrhea and anti-inflammatory effects, providing new therapeutic and preventive strategies.
Patent Information
- Application Number
- CN202310523407.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-10
- Publication Date
- 2024-11-12
AI Technical Summary
Patients with chemotherapy-related diarrhea (CID) lack special drugs and preventive measures. The existing probiotic products are difficult to effectively target the complex pathogenesis of CID, and the probiotics have poor stress resistance, making it difficult to survive and play a role in the gastrointestinal tract.
Develop an enteric capsule containing Fencoli, using Fencoli lyophilized bacteria powder to combine with pharmaceutically acceptable water-absorbent agents to improve the acid resistance of probiotics by optimizing the mass ratio of bacteria powder to water-absorbent agents. Survival rate and stress resistance of the strain is enhanced by specific lyophilized protective agents and formulations.
It significantly improves the diarrhea symptoms induced by chemotherapeutic drugs 5-fluorouracil and irinotecan, has anti-inflammatory effects and antioxidant ability, can inhibit the growth of the pathogen Clostridium difficile, and improves the acid resistance survival rate and patient compliance of enteric capsules.
Smart Images

Figure CN118924694A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of living biological medicines, and in particular relates to an enteric-coated capsule containing Bacillus finschweizoid. Background Art
[0002] Chemotherapy-induced diarrhea (CID) is a common gastrointestinal toxicity caused by chemotherapy in cancer patients. Mild diarrhea can reduce the patient's quality of life, and frequent severe diarrhea may cause dehydration, infection, shock, and even death. Therefore, patients with severe diarrhea need to reduce the dose of chemotherapy drugs or even interrupt chemotherapy, which affects the treatment of tumors.
[0003] Among the commonly used chemotherapy regimens, CapeIRI (capecitabine + irinotecan) and FOLFOXIRI (fluorouracil + leucovorin + oxaliplatin + irinotecan) are most likely to cause CID, with the incidence of grade 3-4 diarrhea as high as 20-47%. Among them, 5-fluorouracil (5-FU) and irinotecan are the drugs most likely to cause CID: 5-FU-related diarrhea is mostly watery or bloody, easily causing sepsis, with a relatively severe degree and occasionally fatal; irinotecan can cause delayed diarrhea, which usually occurs after 24 hours and lasts for 6-14 days, is unrelated to the dose and is unpredictable.
[0004] Compared with common diarrhea, the pathogenesis of CID is more complicated. On the one hand, chemotherapy drugs (e.g., 5-FU) can cause DNA damage and mitochondrial dysfunction, intestinal epithelial cell apoptosis, overactivation of transcription factor NF-κB, and upregulation of proinflammatory cytokines after treatment, ultimately leading to damage to the epithelium, endothelium, and connective tissue. On the other hand, there are many other factors that have the risk of causing diarrhea in cancer patients treated with 5-FU or irinotecan. For example, due to damage to the intestinal barrier, the integrity of the mucosa and the intestinal flora are destroyed, and harmful bacteria are very easy to proliferate, such as high-risk pathogens of hospital infection such as Clostridium difficile.
[0005] According to the 2018 ESMO (European Society for Medical Oncology) guidelines for diarrhea in adult cancer, currently, symptomatic treatments such as antidiarrheal drugs, somatostatin analogs, glucocorticoids, and antibiotics are mostly used in clinical practice. There is a lack of special drugs and preventive measures, and the side effects are large. For example, opioids (pelotamide) may cause the risk of paralytic ileus when used in large doses; somatostatin analogs (octreotide) can cause side effects such as gallstones, hyperglycemia, and impaired glucose tolerance; glucocorticoids may have systemic effects, increase the risk of infection, and aggravate viral or bacterial infections. Epidemiological data show that the number of cancer patients worldwide increases significantly every year. It is estimated that by 2040, about 3 to 7 million people will suffer from chemotherapy-related side effects, but the current treatment plan lacks special drugs and preventive measures, which makes it difficult to meet the growing clinical needs.
[0006] The intestinal microecology system is the largest and most important microecology system in the body. Imbalance of the intestinal microecology is closely related to the pathogenesis of many diseases. A large number of studies have shown that intestinal probiotics can regulate the body's tissues, organ functions and behaviors through the intestinal nerves, immune system, intestinal endocrine signals and other pathways, thereby benefiting the host's health. However, in recent years, there has been a lack of large-scale, high-quality, prospective randomized controlled trials on the efficacy of probiotics in preventing and treating radiotherapy-related diarrhea. In addition, the studies included in the current systematic analysis have obvious heterogeneity and cannot form strong definitive evidence. Rigorous clinical research is still needed to clarify. In addition, the probiotic products on the market that relieve diarrhea symptoms are all traditional first-generation probiotics, which are difficult to play a good therapeutic role in the complex pathogenesis of CID.
[0007] At present, no studies have reported that Bacillus finschweisenii can be used to treat and / or prevent chemotherapy-related diarrhea. Patent CN113999922A discloses acute diarrhea marker microorganisms and their applications, which focus on studying the changes in microbial abundance in fecal samples of patients with acute diarrhea. The pathogenesis of chemotherapy-related diarrhea is more complicated than that of general diarrhea, and clinically there are both acute and chronic diarrhea manifestations. Therefore, in order to meet the needs of patients with chemotherapy-related diarrhea for live bacterial preparations with targeted therapeutic effects, it is necessary to develop a new probiotic preparation.
[0008] In addition, probiotic drugs have poor stress resistance and are easily damaged by low pH and low redox potential when taken orally and passing through the stomach. Moreover, probiotic products usually use freeze-dried bacterial powder as the active ingredient and are also very sensitive to water. Their tolerance becomes even worse after being activated by water. These combined factors make it so that very few probiotics can survive and reach the intestines to exert their effects. Summary of the invention
[0009] The present invention aims at the shortcomings of the prior art for treating diarrhea caused by chemotherapy drugs, and provides an enteric-coated capsule containing Bacillus finschii. The capsule is filled with freeze-dried bacterial powder of Bacillus finschii and a pharmaceutically acceptable water absorbent, the mass ratio of the freeze-dried bacterial powder to the water absorbent is 1:(3-8), and the Bacillus finschii is a strain with a preservation number of CCTCC No: M20221759 or its progeny strain, cloned strain and pure culture.
[0010] In some specific embodiments, the water absorbent is selected from one or more of anhydrous calcium chloride, anhydrous sodium acetate, anhydrous sodium acetate, anhydrous sodium sulfate, anhydrous magnesium sulfate, anhydrous magnesium chloride, anhydrous sodium phosphate, and anhydrous calcium sulfate.
[0011] In some specific embodiments, the mass ratio of the freeze-dried bacterial powder to the water absorbent is 1:(3-7); in some specific embodiments, the mass ratio of the freeze-dried bacterial powder to the water absorbent is 1:(3-6); in some specific embodiments, the mass ratio of the freeze-dried bacterial powder to the water absorbent is 1:(3-5). If the content of the water absorbent is too low, the capsule's isolation effect on gastric acid or water will be affected, and the acid-resistant survival rate of the probiotics will not meet the requirements; if the content of the water absorbent is too high, the drug loading will be low, the number of capsules for a single dose will increase, and the patient's compliance will be poor.
[0012] In some embodiments, the freeze-dried bacterial powder is prepared by 7 -1×10 11 The bacterial mud concentrate with a concentration of CFU / mL was added to a freeze-drying protective agent containing 120 g / L sucrose, 40 g / L sorbitol, 40 g / L arginine hydrochloride, and 40 g / L sodium vitamin C, and freeze-dried to obtain the concentrate.
[0013] In some specific embodiments, a single enteric-coated capsule contains 30-100 mg of bacterial powder; in some specific embodiments, the enteric-coated capsule contains 40-90 mg of bacterial powder; in some specific embodiments, the enteric-coated capsule contains 40-80 mg of bacterial powder; in some specific embodiments, the enteric-coated capsule contains 40-70 mg of bacterial powder; in some specific embodiments, the enteric-coated capsule contains 40-60 mg of bacterial powder; in some specific embodiments, the enteric-coated capsule contains 40-50 mg of bacterial powder; in some specific embodiments, the enteric-coated capsule contains 40 or 50 mg of bacterial powder.
[0014] In some embodiments, a single enteric-coated capsule contains 100-150 mg of a water absorbing agent.
[0015] The colony culture characteristics of the Alistipes finegoldii of the present invention on the BHI+MRS+modified GAM three-mixed culture medium are: smaller white opaque, convex round colonies with smooth and moist surfaces; the strain morphology is identified by crystal violet staining, and the above-mentioned Alistipes finegoldii is short rod-shaped under an optical microscope.
[0016] The finschweig-like bacillus of the present invention is sensitive to at least one of the following nine antibiotics: imipenem, vancomycin, tetracycline, erythromycin, clindamycin, levofloxacin, nitrofurantoin, high-concentration gentamicin, and rifampicin.
[0017] The genome of the Allebacterium finschii of the present invention has no virulence gene and is non-hemolytic in vitro (ie, γ-hemolytic).
[0018] The present invention also provides the use of the above-mentioned Alistipes finegoldii in the preparation of a microbial preparation, wherein the microbial preparation is used for treating and / or preventing diarrhea caused by chemotherapy drugs and / or inhibiting the reproduction of intestinal pathogens.
[0019] Preferably, the microbial preparation has an inhibitory effect on Clostridium difficile.
[0020] Preferably, the chemotherapy drugs include but are not limited to: fluorouracils, topoisomerase I inhibitors, tyrosine kinase inhibitors, taxanes, platinum chemotherapy drugs and other types of chemotherapy drugs.
[0021] Optionally, the fluorouracils include 5-fluorouracil, tegafur, capecitabine, etc.; the topoisomerase I inhibitors include irinotecan, topotecan, etc.; the tyrosine kinase inhibitors include gefitinib, erlotinib, lapatinib, afatinib, dacomitinib, vandetanib, neratinib, osimertinib, imatinib, dasatinib, nilotinib, bosutinib, ponatinib, etc.; the taxane chemotherapy drugs include paclitaxel, docetaxel, etc.; the platinum chemotherapy drugs include cisplatin, oxaliplatin, etc.
[0022] Preferably, the chemotherapy drug is 5-fluorouracil and / or irinotecan;
[0023] Preferably, the microbial preparation is used to alleviate diarrhea symptoms caused by 5-fluorouracil and / or irinotecan;
[0024] Preferably, the microbial preparation can significantly reduce the expression of TNF-α, a pro-inflammatory factor in THP-1 cells, and has an anti-inflammatory effect;
[0025] Preferably, the microbial preparation has significant antioxidant capacity.
[0026] In a preferred embodiment of the present invention, the microbial preparation may include Bacillus finschii cells and / or Bacillus finschii fermentation supernatant and / or Bacillus finschii lysate.
[0027] The present invention has the following beneficial effects:
[0028] 1. The finnsii-like Bacillus Afine-1 of the present invention is different from traditional probiotics and other existing products under development on the market, and belongs to a newer species. Experiments have confirmed that the strain is sensitive to a variety of antibiotics, is not hemolytic, and has no virulence factors as shown by whole genome analysis, indicating that the strain has good safety. In terms of effectiveness, the strain can not only significantly improve the diarrhea symptoms induced by chemotherapy drugs 5-fluorouracil and irinotecan, but also has anti-inflammatory and antioxidant effects, and can inhibit the growth of the pathogen Clostridium difficile. Therefore, the finnsii-like Bacillus Afine-1 of the present invention can be applied to a new generation of live bacterial microecological preparations, providing new ideas and strategies for the prevention and (or) treatment of CID from multiple aspects.
[0029] 2. The present invention provides an enteric-coated capsule for Afine-1. Compared with ordinary enteric-coated capsules, the acid-resistant survival rate is greatly improved by filling with a water absorbent.
[0030] Strain preservation information: Deposited in China Center for Type Culture Collection (CCTCC, Wuhan University Collection Center) on November 10, 2022, with the preservation number CCTCC No: M 20221759. BRIEF DESCRIPTION OF THE DRAWINGS
[0031] Figure 1 This is the result graph of the antioxidant capacity of Afine-1.
[0032] Figure 2 This is a graph showing the results of Alternaria fischeri Afine-1 inhibiting the expression of the pro-inflammatory factor TNF-α in THP-1 cells.
[0033] Figure 3 This figure shows the improvement effect of Afine-1 on 5-fluorouracil-induced diarrhea in mice (A is the daily diarrhea score results of each group of mice during the experiment; B is the diarrhea score results of each group of mice on the 9th day; C is the total diarrhea score results of each group of mice during the experiment).
[0034] Figure 4 This is a diagram showing the improvement effect of Afine-1 on irinotecan-induced diarrhea in mice (A is the daily diarrhea score of mice in each group during the experiment; B is the total diarrhea score of mice in each group during the experiment) DETAILED DESCRIPTION
[0035] The technical solutions in the embodiments of the present invention will be described clearly and completely below: Obviously, the described embodiments are only part of the embodiments of the present invention, rather than all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without making creative work should fall within the scope of protection of the present invention.
[0036] The culture medium preparation method used in the following examples is as follows:
[0037] Preparation of YCFA liquid medium: weigh 10.0 g of casein peptone, 2.5 g of yeast extract, 0.45 mL of 10 mg / mL magnesium sulfate heptahydrate solution, 0.45 mL of calcium chloride (10% mother solution), 10 mL of TE141, 0.45 g of dipotassium hydrogen phosphate, 0.45 g of potassium dihydrogen phosphate, 0.90 g of sodium chloride, and 3.2 mL of VFA-mix, and dissolve them in 1 L of distilled water. 2 Replace and deoxygenate, repackage, sterilize at 121℃ for 30min, store in a cool, dry place for later use.
[0038] Preparation of TE141: Weigh 1.50 g of nitrilotriacetic acid (NTA) and add it to 200 mL of pure water. Add an appropriate amount of NaOH until the solution becomes clear. Then add 800 mL of water and adjust the pH value to 5.5 with 50% HCl. Then weigh MgSO 4 7H 2 O 3.00g, MnSO 4 ·H 2 O 0.50g, NaCl 1.00g, FeSO 4 7H 2 O 0.10g, CoSO 4 7H 2 O 0.18 g, CaCl 2 ·2H 2 O 0.10g, ZnSO 4 7H 2 O0.18g,CuSO 4 ·5H 2 O 0.006g, KAl(SO 4 ) 2 12H 2 O 0.02g, H 3 BO 3 0.01g, Na 2 MoO 4 ·2H 2 O 0.01g, NiCl 2 6H 2O 0.03 g, 10 mg / mL Na 2 SeO 3 ·5H 2 O solution 0.03 mL, 10 mg / mL Na 2 WO 4 ·2H 2 Add 0.03 mL of O solution to the above test solution, stirring continuously during the addition process to keep the solution clear for later use.
[0039] Preparation of VFA-mix: Measure 90 mL of acetic acid, 30 mL of propionic acid, 10 mL of n-valeric acid, 10 mL of isobutyric acid, and 10 mL of butyric acid, mix well for later use, and adjust to neutrality with 5 M NaOH before use.
[0040] Preparation of triple mixed medium (BHI+MRS+modified GAM): weigh 19.25 g of BHI broth powder (Qingdao Haibo Biotechnology Co., Ltd., HB8297-5), 13.5 g of MRS broth powder (Guangdong Huankai Biotechnology Co., Ltd., 027312), and 15 g of modified GAM broth powder (Qingdao Haibo Biotechnology Co., Ltd., HB8518-3) (add 12 g of agar powder when preparing triple mixed solid medium), dissolve in 1 L of distilled water, N 2 Replace and deoxygenate, repackage, sterilize at 121℃ for 30min, and store in a cool, dry place.
[0041] Preparation of BF839 medium: Weigh 6.0 g potato extract powder (Beijing Solebow Technology Co., Ltd., FA0270), 10.0 g polyvalent peptone (Beijing Solebow Technology Co., Ltd., P8950-250), 5.0 g phenoxyethanol (Qingdao High-tech Industrial Park Haibo Biotechnology Co., Ltd., HB8277), 0.3 g sodium thioglycolate (Shanghai Aladdin Biochemical Technology Co., Ltd., S105664-25G), 5.0 g yeast extract powder (UK OXOID Company, LP0021B), 1.5 g glucose (Chengdu Kelong Chemical Co., Ltd., 50-99-7), 4.0 g disodium hydrogen phosphate (Chengdu Kelong Chemical Co., Ltd., 7558-79-4), and dissolve in 1 L of distilled water. 2 Replace and deoxygenate, repackage, sterilize at 121℃ for 30min, and store in a cool, dry place.
[0042] GAM solid culture medium (Qingdao Haibo Biotechnology Co., Ltd., HB8462), TSB (Tryptone Soy Broth, Qingdao Haibo Biotechnology Co., Ltd., HB4114), and TSA (Tryptone Soy Agar, Qingdao Haibo Biotechnology Co., Ltd., HB4138) were prepared according to the instructions, weighed and dissolved, sterilized at 121°C for 30 min, and stored in a cool and dry place.
[0043] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.
[0044] Example 1 Isolation, purification and colony identification of Afine-1
[0045] (1) Collect fresh fecal samples from healthy volunteers, add appropriate amount of oxygen-free PBS to resuspend, and shake until the sample is fully resuspended. 2 Under protection, filter with a single layer of gauze, and dispense the filtrate into 50mL centrifuge tubes, then filter once with a double layer of gauze, centrifuge at 10000rpm for 20min, and discard the supernatant. Add an appropriate amount of oxygen-free PBS to resuspend the bacteria, then add an equal volume of 50% oxygen-free glycerol to mix thoroughly, and dispense into 2mL screw cap tubes, 0.5mL each. After dispensing, bag and vacuum-pack in a -80℃ refrigerator for later use.
[0046] (2) During separation, take out one frozen sample tube, weigh the thawed sample at a ratio of 1:10 and resuspend it in anaerobic PBS. After vortexing for 5 min, transfer it into the anaerobic glove box, take 0.5 mL of the bacterial suspension and vortex and mix it in 4.5 mL of anaerobic PBS, and then dilute it to 10 -6 , take appropriate gradient bacterial solution and mix with YCFA medium, then divide into 384-well plates and culture for one week. Pick the bacterial solution from the growing wells for transfer. After 48 hours of culture, one copy is detected by MALDI-TOF-MS to preliminarily classify the isolated strains; the other copy is transferred to a 96-well plate again according to the mass spectrometry results, in duplicate. After 48 hours of culture, one plate is amplified for 16S rDNA gene and sent to Chengdu Branch of Beijing Qingke Biotechnology Co., Ltd. for sequencing, and the other plate is temporarily stored by adding 50% glycerol at a ratio of 1:1 and used after the PCR results are confirmed.
[0047] (3) The 16S rDNA gene sequencing results were analyzed and the sequences were compared with the NCBI Nucleotide database. The results showed that the sequence similarity with a strain of Alistipes finegoldii was the highest (>99.9%). Therefore, it was preliminarily identified as Alistipes finegoldii and named Alistipes finegoldii Afine-1. The strain appeared as small white opaque, convex round, smooth and moist colonies on a three-mixed solid medium (BHI+MRS+modified GAM); the crystal violet staining method was used to identify the strain morphology. Alistipes finegoldii Afine-1 appeared as a short rod under an optical microscope. The strain was deposited in the China Center for Type Culture Collection (CCTCC, Wuhan University Collection Center) on November 10, 2022, and the strain deposit number is CCTCC No: M 20221759.
[0048] Example 2 Whole genome analysis of Afine-1
[0049] Afine-1 was inoculated into 5 mL of anaerobic three-mixed medium at a 2% inoculum and cultured until the late logarithmic growth period. The whole genome DNA of the strain was extracted and the whole genome was sequenced using the Illumina high-throughput sequencing platform NovaSeq 6000. After assembly and annotation, the protein sequence was entered into the Virulence Factor Databases for virulence factor analysis. The results showed that the bacteria did not have virulence factors.
[0050] The average nucleotide similarity (ANI) was used to analyze the novelty of the strain. By searching in Genbank, 37 published Alistipes finegoldii genomes were found. By comparing with fastANI (v1.33), it was found that the two strains closest to the full genome of Alistipes finegoldii were GCA_014845615.1 (ANI = 99.27%) and GCA_928722145.1 (ANI = 99.25%), both lower than 99.9%, so Alistipes finegoldii Afine-1 can be considered a new strain.
[0051] Example 3 Hemolysis test of Afine-1
[0052] The preserved Afine-1 was inoculated into 5mL anaerobic three-mixed medium (BHI+MRS+modified GAM) at a 2% inoculation rate, Enterococcus faecalis (β-hemolytic, CICC23658, China Industrial Microbiological Culture Collection Management Center) was used as a positive control, and a blank medium was used as a negative control. All strains were cultured anaerobically at 37°C for 12 hours in anaerobic three-mixed medium to obtain activated strains. 2.5μL of activated bacterial solution was inoculated on Columbia blood plates (Shanghai Chromagar Microbiological Technology Co., Ltd.), and 3 parallels were set for each strain. After anaerobic culture at 37°C for 48 hours, observation was performed. A clear-cut and completely transparent hemolytic ring was formed around the colony of Enterococcus faecalis as a positive control, which was β-hemolysis; the culture medium around the colony of Afine-1 did not change, which was γ-hemolysis, that is, no hemolysis.
[0053] Example 4 Antibiotic sensitivity test of Alternaria finschii Afine-1
[0054] According to the requirements of antibiotic sensitivity test in Part III "General Theory of Microecological Live Bacteria Preparations" of the "Chinese Pharmacopoeia" (2020 edition), the agar diffusion paper method was used to determine the sensitivity of the strain to antibiotics, and the antibiotic sensitivity level of the strain was judged according to the size of the inhibition zone.
[0055] Strain activation and streaking: Afine-1 was activated in a three-mixed medium (BHI+MRS+modified GAM), cultured anaerobically at 37°C for 24 h, a loopful of the bacterial liquid was streaked on a Brunner solid medium, and the plate was placed for anaerobic culture at 37°C; Staphylococcus aureus (CMCC(B)26003, China Food and Drug Inspection Institutes) was activated in TSB liquid medium, cultured aerobically at 37°C for 24 h, a loopful of the bacterial liquid was streaked on a TSA solid medium, and the plate was placed for aerobic culture at 37°C.
[0056] Preparation of bacterial suspension: Pick several single colonies from the cultured solid plate and inoculate them into physiological saline to make a bacterial suspension, and adjust the turbidity of the suspension to 0.5 McFarland concentration.
[0057] Inoculation plate: Dip a sterile cotton swab into the bacterial solution and rotate and squeeze out the excess bacterial solution on the inner wall of the tube; spread it evenly on the surface of the Brucella plate (Bacillus finnsii group) or TSA plate (Staphylococcus aureus group) for 3 times, rotating the plate 60 degrees each time, and finally spread it along the edge of the agar in the plate for one week (completed within 15 minutes).
[0058] Antimicrobial drug paper strips: Use a drug sensitive paper strip dispenser to distribute the drug sensitive paper strips on the flat plate, place 3 drug sensitive paper strips on each flat plate, and set up 3 parallels. The specific information of 14 drug sensitive paper strips (Wenzhou Kangtai Biotechnology Co., Ltd.) is shown in Table 1.
[0059] Table 1 Information on 14 drug-sensitive paper strips
[0060]
[0061] The experimental results are as follows: Staphylococcus aureus was used as a quality control strain, and the results were all within the drug sensitivity range. Afine-1 was sensitive to 9 antibiotics: imipenem, vancomycin, tetracycline, erythromycin, clindamycin, levofloxacin, nitrofurantoin, high-concentration gentamicin, and rifampicin; it was resistant to 2 antibiotics: penicillin and ampicillin; it was intermediate to 3 antibiotics: ceftriaxone, trimethoprim, and streptomycin.
[0062] Example 5 Antioxidant experiment of Alternaria finschii Afine-1
[0063] The preserved Afine-1 was activated and inoculated into 5 mL of anaerobic BF839 medium at a 2% inoculation rate. LGG (Lactobacillus rhamnosus GG, CICC6141, China Industrial Microbiological Culture Collection Center) was used as a positive control. All strains were anaerobically cultured in anaerobic BF839 medium at 37°C for 24 h.
[0064] Sample processing: Take 0.5mL of culture solution and centrifuge at 12000rpm for 20min, discard the supernatant, and resuspend with 0.5mL of pre-cooled extraction solution; transfer to a sterilized screw-cap tube containing beads (Sigma, USA, G4649-1KG), oscillate and break the wall once with a rapid sample preparation instrument (parameter setting: 4.5m / s, 30s), then centrifuge at 12000rpm and 4℃ for 10min, take the supernatant and place it on ice for testing.
[0065] BCA protein concentration determination (Beijing Solebow Technology Co., Ltd., PC0020):
[0066] 1) Solution preparation: According to the number of standards and samples, add 50 volumes of BCA reagent to 1 volume of Cu reagent (50:1) to prepare BCA working solution and mix thoroughly.
[0067] 2) Standard curve drawing: Take 10μL BSA standard and dilute it to 100μL with PBS to make the final concentration 0.5mg / mL; add 0, 2, 4, 6, 8, 12, 16, 20μL of the standard to the protein standard wells of the 96-well plate, and add PBS to make up to 20μL. Add 200μL BCA working solution to each well, place at 37℃ for 15-30min, and measure the absorbance at A562 nm.
[0068] 3) Sample detection: Add 200 μL of BCA working solution to each sample to be tested, place at 37°C for 15-30 min, and measure the absorbance at A562 nm.
[0069] Total antioxidant capacity test of strains (Beijing Solebow Technology Co., Ltd., BC1315):
[0070] 1) Solution preparation: Pre-cool the extract in a refrigerator at 2-8°C or on ice before use. Add 10 mg FeSO 4 7H 2 O standard was added to 0.9 mL of distilled water and 20 μL of concentrated sulfuric acid to prepare 40 μmol / mL FeSO 4 The standard solution is ready for use; mix reagent 1, reagent 2, and reagent 3 in the kit in a ratio of 7:1:1 to make a working solution, which is ready for use and preheated in a 37°C constant temperature incubator for 10 minutes before use.
[0071] 2) Standard curve drawing: Dilute the 40 μmol / mL standard solution with distilled water to 0.15, 0.1, 0.05, 0.025, 0.0125, 0.00625, and 0.003125 μmol / mL standard solutions for use. 2+ The final concentrations were 0.075, 0.05, 0.025, 0.0125, 0.00625, 0.003125, and 0.00156 μmol / mL, respectively. Pipette 100 μL of the standard solution (with distilled water as blank) and add 100 μL of reagent 2 in the kit, mix thoroughly, react at room temperature for 10 minutes, and measure the absorbance at 593 nm.
[0072] 3) Sample detection: Add 180 μL of working solution, 6 μL of sample to be tested, and 18 μL of distilled water to a 96-well plate, mix thoroughly, react at room temperature for 10 min, and measure the absorbance at 593 nm.
[0073] Calculation formula:
[0074] 1) Calculate the sample protein concentration based on the protein standard curve.
[0075] 2) Calculate the sample Fe based on the antioxidant standard curve 2+ concentration.
[0076] 3) Calculation of total antioxidant capacity:
[0077] Total antioxidant capacity (μmol / mg prot) = x × V total ÷ (V sample × Cpr) = 34 × x ÷ Cpr
[0078] x: Fe in the sample 2+ Final concentration, μmol / mL; V total: total reaction volume, 0.204 mL;
[0079] Vsample: sample volume in the reaction, 0.006 mL; Cpr: sample protein concentration, mg / mL.
[0080] Experimental results: Figure 1 It can be seen that the total antioxidant capacity of the positive control strain LGG reached 0.25μmol / mg prot, and the total antioxidant capacity of Afine-1 reached 0.36μmol / mg prot, which was significantly stronger than LGG (p<0.05), indicating that Afine-1 has a strong antioxidant capacity.
[0081] Example 6 Evaluation of the antibacterial activity of Afine-1 against Clostridium difficile
[0082] After activation, the finnella-like Bacillus Afine-1 was inoculated in an anaerobic three-mixed medium (BHI+MRS+modified GAM) at a 2% inoculation rate and cultured at 37°C for 48 hours to obtain a fermentation liquid. At the same time, Clostridium difficile (CICC22951, China Industrial Microbiological Culture Collection Management Center) was activated and transferred, and then diluted 50 times in a sterile anaerobic three-mixed liquid medium as a pathogenic bacteria liquid; 0.2mL of the pathogenic bacteria liquid was spread on a sterile anaerobic GAM solid medium (+5% horse serum). Three sterilized Oxford cups were placed on the plate after coating, and 0.2mL of finnella-like Bacillus fermentation liquid was added to the Oxford cup. Put it in an anaerobic culture box, add an anaerobic gas-producing bag, and culture the plate upright for 24 hours, and then measure the size of the inhibition zone with a vernier caliper. The results showed that the diameter of the inhibition zone of finnella-like Bacillus Afine-1 against Clostridium difficile was 15.00mm, indicating that it has antibacterial ability against Clostridium difficile.
[0083] Example 7 In vitro cell inflammation inhibition test of Afine-1
[0084] THP-1 cell polarization: THP-1 is a suspension cell (Shangcheng Beina Chuanglian Biotechnology Co., Ltd., BNCC No. 358410), and PMA (phorbol 12-myristate 13-acetate, Sigma-Aldrich Company, P1585) is used to induce THP-1 to polarize into mature macrophages. On the basis of THP-1 differentiation into mature macrophages, lipopolysaccharides (LPS, Sigma-Aldrich Company, L3024) and interferon-γ (interferon-gamma, IFN-γ, Paiptech Biotechnology (Suzhou) Co., Ltd., AF-30-02-20) are further used to induce mature macrophages to polarize into inflammatory macrophages. RPMI-1640 (Thermo Fisher Scientific (China) Co., Ltd., C11875500BT) medium containing 10% FBS (Thermo Fisher Scientific (China) Co., Ltd., SH30084.03) and a final concentration of 100 ng / mL PMA was used. 5 THP-1 cells were seeded in 96-well plates at a seeding density of 1 / well and placed in a 5% CO 2 After culturing for 24 h at 37°C in an incubator, the medium was replaced with RPMI-1640 medium containing 10% FBS, LPS with a final concentration of 100 ng / mL, and 20 ng / mL IFN-γ. 2 Incubate at 37°C in an incubator for 24 h.
[0085] Strain culture: Take 200 μL of Afine-1 bacterial solution from the bacterial storage to 5 mL of anaerobic three-mixed culture medium (BHI+MRS+modified GAM), and culture anaerobically in a 37°C electric constant temperature incubator for 24 hours. After transferring once, culture anaerobically for 8 hours. Take 1 mL of bacterial solution, centrifuge at 5000 rpm / min for 15 minutes. Dilute the strain to 3.67×10 with RPMI-1640 medium containing 10% FBS. 6 CFU / mL is reserved.
[0086] Effect of Afine-1 on TNF-α expression in THP-1 cells: The culture medium of mature macrophages was removed and 100 μL of RPMI-1640 culture medium containing 10% FBS was added as the normal control group. The inflammatory macrophages polarized in advance were added with 100 μL of RPMI-1640 culture medium containing 10% FBS as the model group; the inflammatory macrophages polarized in advance were added with 100 μL of RPMI-1640 culture medium containing 10% FBS and dexamethasone (Sigma-Aldrich Company, D4902-25) at a final concentration of 25 μg / mL as the positive control group, and the experimental group was added with 100 μL of the previously prepared Afine-1 bacterial solution. Placed in 5% CO 2 Incubator, 37°C for 24 h. Pipette 80 μL of cell culture medium, centrifuge at 4°C, 5000 rpm / min for 15 min, collect the supernatant, and use Human TNF-α (Tumor Necrosis Factor Alpha) ELISA kit to detect TNF-α content (Wuhan Elaruite Biotechnology Co., Ltd., E-EL-H0109c).
[0087] Experimental results: Figure 2 As shown, compared with the model group, Afine-1 can significantly inhibit the expression of proinflammatory factor TNF-α in inflammatory macrophages THP-1, indicating that this strain has a very obvious anti-inflammatory effect.
[0088] Example 8 The therapeutic effect of Afine-1 on 5-fluorouracil-induced diarrhea in mice
[0089] Preparation of freeze-dried protective agent: Weigh 10g of trehalose, 5g of oligofructose, and 10g of skim milk powder, dissolve in 70g of purified water, and sterilize at 115℃ for 20min. Add 5g of sodium vitamin C before use.
[0090] Preparation of bacterial powder: The preserved Afine-1 was inoculated into an anaerobic three-mixed culture medium (BHI+MRS+modified GAM) at a 10% inoculation rate, and cultured anaerobically at 37°C and 150rpm for 18-24h until OD600 The value is ≥0.8, and the first-level seed solution is obtained. The inoculation amount is transferred to the anaerobic three-mixed culture medium again at 1.5%, and anaerobically cultured at 37°C and 150rpm for 18-24h until the OD 600 The value is ≥1.0, and the secondary seed solution is obtained. The inoculum volume is pumped into the fermentation tank with modified GAM broth using a peristaltic pump at 1%, and the fermentation parameters are set (temperature 37°C, pH 6.5, speed 150rpm, pressure control 0.06MPa) to start fermentation. The fermentation solution OD 600 Value ≥1.4 or OD 600 When the value increases by ≤0.1, stop fermentation, set the fermentation temperature to 20℃, and collect the bacterial cells. Divide the bacterial liquid into centrifuge buckets, centrifuge and discard the supernatant. Add lyophilization protective agent at a weight ratio of 1:2 to emulsify the bacterial slurry. Place the emulsified bacterial suspension on the plate layer of a freeze dryer cooled to -40℃ for freeze drying. After the freeze drying process is completed, take out the bacterial cake and crush it to obtain the bacterial powder. Before administering the drug to the animals, use 0.2mL of normal saline to mix 1×10 9 CFU bacterial powder is prepared into bacterial suspension.
[0091] Experimental animals: Twenty SPF male Balb / c mice weighing 18-22 g were purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd. and kept in an SPF animal room. The mice were randomly divided into 4 groups according to their initial weight, with 5 mice in each group.
[0092] Experimental design: A 5-FU solution (Tianjin Jinyao Pharmaceutical Co., Ltd., specification 10mL / vial, 0.25g / 10mL) was used to induce a mouse chemotherapy-related diarrhea model. The four groups were normal control group, model control group, positive control loperamide group and Afine-1 group. Except for the normal control group, which was intraperitoneally injected with normal saline, the other groups were treated with a single intraperitoneal injection of 5-FU for modeling, and the modeling dose was 350mg / kg. All groups were administered by gavage. The normal control group and the model control group were administered with lyophilized protective agents. The positive control group was administered with loperamide (Xi'an Janssen Pharmaceutical Co., Ltd.) at a dose of 20mg / kg, and the Afine-1 group was administered with 1×10 9 CFU / each was administered with Afine-1. The overall experimental period was 9 days, i.e. D1-D9. A single 5-FU modeling treatment was performed on D3. The normal control group, model control group and Afine-1 group were given oral administration for 5 consecutive days, and the loperamide group was given once a day for 9 consecutive days. The specific experimental groups and dosing schedules are shown in Table 2.
[0093] Diarrhea test: Place mice in a mouse cage lined with clean filter paper, one per cage. Hard stools and normal stools are scored as 0 points; mild, slightly wet stools or soft stools are scored as 1 point; moderate, wet stools, unformed stools and unclean perianal area are scored as 2 points; severe, loose stools and severe unclean perianal area are scored as 3 points. During the experimental period, the feces of mice were observed and scored every day. The total diarrhea score was the sum of the diarrhea scores for each day.
[0094] The specific experimental groups and dosing regimens are shown in Table 2.
[0095] Table 2 Modeling scheme and dosing regimen for the therapeutic effect of Afine-1 on 5-FU-induced diarrhea mice
[0096]
[0097] Note: 5-FU: 5-fluorouracil; CFU: colony forming unit; d: day
[0098] Experimental results: Figure 3 As shown in the figure, compared with the model control group, loperamide and Afine-1 could significantly reduce the diarrhea score on the 9th day (P<0.01); loperamide could significantly reduce the total diarrhea score (P<0.05), and Afine-1 could significantly reduce the total diarrhea score of mice induced by 5-FU (P<0.01) ( Figure 3 A, B and C).
[0099] The above results indicate that the Alternaria finschii Afine-1 of the present invention can significantly improve the diarrhea symptoms of mice caused by 5-fluorouracil.
[0100] Example 9 The therapeutic effect of Afine-1 on irinotecan-induced diarrhea in mice
[0101] Experimental animals: 24 SPF male Balb / c mice weighing 18-22 g were purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd. and kept in an SPF animal room. The mice were randomly divided into 4 groups according to their initial weight.
[0102] Experimental design: Irinotecan (CPT-11, Shanghai Yuanye Biotechnology Co., Ltd., specification 5g) solution was used to induce chemotherapy-related diarrhea model in mice. The four groups were normal control group (n=5), model control group (n=7), positive control prednisone group (n=6) and Afine-1 group (n=6). Except for the normal control group, which was intraperitoneally injected with normal saline, the other groups were intraperitoneally injected with CPT-11 for 4 consecutive days to establish the model, and the modeling dose was 60mg / kg. All groups were administered by gavage. The normal control group and the model control group were administered with lyophilized protective agent, the positive control group was administered with prednisone (Tianjin Xinyi Jinjin Pharmaceutical Co., Ltd.) at a dose of 100mg / kg, and the Afine-1 group was administered with 1×10 Afine-1 group. 9 CFU / mouse. The overall experimental period was 9 days, i.e. D1-D9. CPT-11 modeling was performed on D3, D4, D5 and D6, once a day. The normal control group, model control group and Afine-1 group were given oral administration for 9 consecutive days, and prednisone was given for 7 consecutive days from D3 to D9, once a day. The specific experimental groups and dosing regimens are shown in Table 3.
[0103] Diarrhea test: Place mice in a mouse cage lined with clean filter paper, one per cage. Hard stools and normal stools are scored as 0 points; mild, slightly wet or soft stools are scored as 1 point; moderate, wet stools, unformed stools and unclean perianal area are scored as 2 points; severe, loose stools and severe unclean perianal area are scored as 3 points. During the experimental period, the feces of mice were observed and scored every day.
[0104] Table 3 Modeling scheme and dosing regimen for the therapeutic effect of Afine-1 on CPT-11-induced diarrhea mice
[0105]
[0106] Note: CPT-11: irinotecan; CFU: colony forming unit; d: day
[0107] Experimental results: Figure 4 As shown, both prednisone and Afine-1 could reduce the diarrhea score starting from the second day after modeling (A); prednisone could significantly reduce the total diarrhea score (P<0.01), and Afine-1 could significantly reduce the total diarrhea score (P<0.05) (B).
[0108] Example 10 Preparation of enteric-coated capsules containing Alternaria finschii Afine-1
[0109] The strain (preservation number: CCTCC NO: M 20221759) was obtained from healthy human feces and can be purified and concentrated by cultivation, centrifugation or filtration. The bacterial sludge concentrate has a viable count of 1×10 7 -1×10 11 CFU / mL. Then add freeze-drying protective agent (sucrose 120g / L, sorbitol 40g / L, arginine hydrochloride 40g / L, vitamin C sodium 40g / L) to the bacterial mud concentrate to 2.5 times the volume of the bacterial mud concentrate, and stir evenly. Pour the bacterial suspension into the freeze-drying plate, cool the plate layer to -40℃, pre-freeze for more than 2h, then evacuate at a vacuum degree of 0.1mbar, and then dry according to the following procedures:
[0110] Temperature ℃ Heating time min Duration min Vacuum degree mbar -30 60 1800 0.1 15 300 90 0.1 25 60 120 0.1 25 1 90 0.0
[0111] The freeze-dried plate was taken out after freeze-drying, and in an environment with humidity less than 30%, the bacterial cake was crushed and passed through a 40-mesh sieve to obtain bacterial powder.
[0112] Preparation of enteric-coated capsules containing Alternaria finschii Afine-1
[0113] Take bacterial powder and water absorbent and mix them evenly according to different mass ratios. Take enteric-coated capsules and fill them with the mixture.
[0114] Depending on the specifications of the capsule, each capsule can be filled with 150-250 mg.
[0115] The water absorbent is selected from anhydrous calcium chloride, anhydrous sodium acetate, anhydrous sodium acetate, anhydrous sodium sulfate, anhydrous magnesium sulfate, anhydrous magnesium chloride, anhydrous sodium phosphate, and anhydrous calcium sulfate.
[0116] By changing the mass ratio of bacterial powder to water absorbent, enteric-coated capsules with different bacterial powder / water absorbent ratios can be prepared. Enteric-coated capsules with better acid-resistant survival rates can be obtained within the mass range of 1:(3-8). Some of the prepared enteric-coated capsules are shown in the following table:
[0117] No. 2 Enteric-coated Gelatin Capsules Contents Capsule 1 40mg bacterial powder + 150mg anhydrous sodium acetate Capsule 2 40mg bacterial powder + 150mg anhydrous sodium sulfate Capsule 3 40mg bacterial powder + 150mg anhydrous calcium sulfate Capsule 4 40mg bacterial powder + 150mg anhydrous magnesium sulfate Comparative Example 1 (without water absorbent) 40mg bacterial powder
[0118] Test example
[0119] Preparation of triple mixed medium (BHI+MRS+modified GAM): weigh 19.25 g of BHI broth powder (Qingdao Haibo Biotechnology Co., Ltd., HB8297-5), 13.5 g of MRS broth powder (Guangdong Huankai Biotechnology Co., Ltd., 027312), and 15 g of modified GAM broth powder (Qingdao Haibo Biotechnology Co., Ltd., HB8518-3) (add 12 g of agar powder when preparing triple mixed solid medium), dissolve in 1 L of distilled water, N 2 Replace and deoxygenate, repackage, sterilize at 121℃ for 30min, and store in a cool, dry place.
[0120] Acid resistance test: Place the capsules in a sinker basket, put them into 250mL of hydrochloric acid solution with a pH of 1.2, and then place them in a constant temperature shaker, shake at 100rpm and 37℃ for 2h, then take out the bacterial powder content and weigh it, and put 180μL of anaerobic PBS buffer into each well of the 96-well plate in the anaerobic glove box. The bacterial powder sample is transferred into the anaerobic glove box, 1mL of anaerobic PBS buffer is added, and the sample is immediately dissolved quickly on an automatic vortex mixer (2000rpm, 1min). Pipette 200μL of the dissolved sample into the 96-well plate in sequence for dilution. Take 100μL of the final concentration of diluted bacterial solution in a plate, pour about 12mL of the above three mixed culture media in half an hour, shake well; let the plate stand to solidify. The plate is inverted in a lock-and-lock box at 37℃, add an anaerobic bag and seal for 36-48h. Count with a plate colony counter and calculate the viable bacteria content.
[0121] Viable bacteria content (cfu / g) = average colony count * dilution factor * (5 + content weight) / 0.1 / content weight.
[0122] Acid resistance survival rate (%) = viable bacteria content of the sample after acid resistance test / viable bacteria content of the sample without acid resistance test*100.
[0123] Table 1 Average survival rate of enteric-coated capsules after acid resistance in Example 10
[0124] Enteric-coated capsules Average survival rate after acid resistance (%) Capsule 1 55.0 Capsule 2 51.9 Capsule 3 52.1 Capsule 4 62.4 Comparative Example 1 (without water absorbent) 8.9
[0125] The enteric-coated capsule of the present invention can well resist gastric acid and improve the survival rate of the capsules reaching the gastrointestinal tract.
Claims
1. An enteric-coated capsule containing Bacillus finschii, wherein the capsule is filled with freeze-dried bacterial powder of Bacillus finschii and a pharmaceutically acceptable water absorbent, wherein the mass ratio of the freeze-dried bacterial powder to the water absorbent is 1: (3-8), the Bacillus finschweigeni is a strain with a deposit number of CCTCC No: M 20221759 or its progeny strain, clone strain and pure culture.
2. The enteric-coated capsule containing Bacillus finschii according to claim 1, It is characterized in that The water absorbing agent is selected from one or more of anhydrous calcium chloride, anhydrous sodium acetate, anhydrous sodium acetate, anhydrous sodium sulfate, anhydrous magnesium sulfate, anhydrous magnesium chloride, anhydrous sodium phosphate, and anhydrous calcium sulfate.
3. The enteric-coated capsule containing Bacillus finschii according to claim 1, It is characterized in that The mass ratio of the freeze-dried bacterial powder to the water absorbent is 1:(3-4).
4. The enteric-coated capsule containing Bacillus finschii according to claim 1, It is characterized in that The freeze-dried bacterial powder is prepared by 7 -1×10 11 The bacterial mud concentrate with a concentration of CFU / mL was added to a freeze-drying protective agent containing 120 g / L sucrose, 40 g / L sorbitol, 40 g / L arginine hydrochloride, and 40 g / L sodium vitamin C, and freeze-dried to obtain the concentrate.
5. The enteric-coated capsule containing Bacillus finschii according to claim 1, It is characterized in that Each enteric-coated capsule contains 30-100 mg of bacterial powder.
6. The enteric-coated capsule containing Bacillus finschii according to claim 1, It is characterized in that A single enteric-coated capsule contains 100-150 mg of water absorbent.
